- Home
- DXLG vs ICCM Comparison
DXLG vs ICCM Comparison
Compare DXLG & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXLG
- ICCM
- Stock Information
- Founded
- DXLG 1976
- ICCM 2006
- Country
- DXLG United States
- ICCM Israel
- Employees
- DXLG N/A
- ICCM N/A
- Industry
- DXLG Clothing/Shoe/Accessory Stores
- ICCM
- Sector
- DXLG Consumer Discretionary
- ICCM
- Exchange
- DXLG Nasdaq
- ICCM Nasdaq
- Market Cap
- DXLG 55.4M
- ICCM 61.1M
- IPO Year
- DXLG 1987
- ICCM N/A
- Fundamental
- Price
- DXLG $1.41
- ICCM $1.02
- Analyst Decision
- DXLG Strong Buy
- ICCM Strong Buy
- Analyst Count
- DXLG 1
- ICCM 1
- Target Price
- DXLG $2.50
- ICCM $2.00
- AVG Volume (30 Days)
- DXLG 216.3K
- ICCM 2.2M
- Earning Date
- DXLG 08-27-2025
- ICCM 08-13-2025
- Dividend Yield
- DXLG N/A
- ICCM N/A
- EPS Growth
- DXLG N/A
- ICCM N/A
- EPS
- DXLG N/A
- ICCM N/A
- Revenue
- DXLG $447,744,000.00
- ICCM $2,787,000.00
- Revenue This Year
- DXLG N/A
- ICCM $3.95
- Revenue Next Year
- DXLG $3.56
- ICCM $266.15
- P/E Ratio
- DXLG N/A
- ICCM N/A
- Revenue Growth
- DXLG N/A
- ICCM N/A
- 52 Week Low
- DXLG $0.90
- ICCM $0.48
- 52 Week High
- DXLG $3.10
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- DXLG 56.66
- ICCM 51.92
- Support Level
- DXLG $1.20
- ICCM $0.98
- Resistance Level
- DXLG $1.52
- ICCM $1.11
- Average True Range (ATR)
- DXLG 0.08
- ICCM 0.06
- MACD
- DXLG 0.01
- ICCM -0.00
- Stochastic Oscillator
- DXLG 65.62
- ICCM 12.12
About DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.